Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1995 3
1996 2
1997 2
1998 4
1999 13
2000 12
2001 13
2002 13
2003 19
2004 13
2005 15
2006 12
2007 13
2008 12
2009 9
2010 6
2011 12
2012 12
2013 13
2014 12
2015 12
2016 8
2017 9
2018 11
2019 10
2020 5
2021 8
2022 7
2023 4
2024 4
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

264 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Evidence on the neuroprotective properties of brimonidine in glaucoma.
Scuteri D, Bagetta G, Nucci C, Aiello F, Cesareo M, Tonin P, Corasaniti MT. Scuteri D, et al. Prog Brain Res. 2020;257:155-166. doi: 10.1016/bs.pbr.2020.07.008. Epub 2020 Aug 6. Prog Brain Res. 2020. PMID: 32988470
OBJECTIVES: this systematic review and meta-analysis aims at assessing the efficacy of brimonidine on visual field deterioration during glaucoma through the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) approach. ...CONCLUSIONS: the evidence o …
OBJECTIVES: this systematic review and meta-analysis aims at assessing the efficacy of brimonidine on visual field deterioration duri …
Interventions for rosacea.
van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. van Zuuren EJ, et al. Cochrane Database Syst Rev. 2015 Apr 28;2015(4):CD003262. doi: 10.1002/14651858.CD003262.pub5. Cochrane Database Syst Rev. 2015. PMID: 25919144 Free PMC article. Review.
Topical interventions: metronidazole, azelaic acid, ivermectin, brimonidine or other topical treatments. Systemic interventions: oral antibiotics, combinations with topical treatments or other systemic treatments, i.e. isotretinoin. ...AUTHORS' CONCLUSIONS: There was high …
Topical interventions: metronidazole, azelaic acid, ivermectin, brimonidine or other topical treatments. Systemic interventions: oral …
Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine.
Tanihara H, Yamamoto T, Aihara M, Koizumi N, Minami H, Kojima S, Isobe T, Kanazawa M, Suganami H; K-232 Clinical Study Group. Tanihara H, et al. Adv Ther. 2023 Aug;40(8):3559-3573. doi: 10.1007/s12325-023-02534-w. Epub 2023 Jun 18. Adv Ther. 2023. PMID: 37330927 Free PMC article. Clinical Trial.
Subjects received twice-daily instillation of RBFC ripasudil brimonidine (group A), ripasudil brimonidine RBFC (group B), or brimonidine RBFC ripasudil (group C). ...Transient morphologic changes in corneal endothelial cells occurred for up to several hours w …
Subjects received twice-daily instillation of RBFC ripasudil brimonidine (group A), ripasudil brimonidine RBFC (group B), or …
Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, Wormald R, Dickersin K. Li T, et al. Ophthalmology. 2016 Jan;123(1):129-40. doi: 10.1016/j.ophtha.2015.09.005. Epub 2015 Oct 31. Ophthalmology. 2016. PMID: 26526633 Free PMC article. Review.
The mean reductions (95% credible intervals) in IOP in millimeters of mercury at 3 months ordered from the most to least effective drugs were as follows: bimatoprost 5.61 (4.94; 6.29), latanoprost 4.85 (4.24; 5.46), travoprost 4.83 (4.12; 5.54), levobunolol 4.51 (3.85; 5.24), taf …
The mean reductions (95% credible intervals) in IOP in millimeters of mercury at 3 months ordered from the most to least effective drugs wer …
Brinzolamide-brimonidine fixed combination for the prevention of intraocular pressure elevation after phacoemulsification.
Georgakopoulos CD, Kagkelaris K, Pagoulatos D, Plotas P, Makri OE. Georgakopoulos CD, et al. Eur J Ophthalmol. 2020 Mar;30(2):293-298. doi: 10.1177/1120672118817997. Epub 2018 Dec 10. Eur J Ophthalmol. 2020. PMID: 30526051 Clinical Trial.
AIM: To evaluate the effectiveness of brinzolamide-brimonidine fixed combination to control the intraocular pressure elevation throughout the first 24 h following uncomplicated phacoemulsification cataract surgery. PATIENTS AND METHODS: A total of 62 patients who underwent …
AIM: To evaluate the effectiveness of brinzolamide-brimonidine fixed combination to control the intraocular pressure elevation throug …
Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial.
McLaurin E, Cavet ME, Gomes PJ, Ciolino JB. McLaurin E, et al. Optom Vis Sci. 2018 Mar;95(3):264-271. doi: 10.1097/OPX.0000000000001182. Optom Vis Sci. 2018. PMID: 29461408 Free PMC article. Clinical Trial.
PURPOSE: The aim of this study was to evaluate the safety and efficacy of brimonidine tartrate ophthalmic solution 0.025% for the treatment of ocular redness. METHODS: In this single-center, double-masked, phase 3 clinical trial, adult subjects with baseline redness …
PURPOSE: The aim of this study was to evaluate the safety and efficacy of brimonidine tartrate ophthalmic solution 0.025% for …
Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study.
Inatani M, Orii Y, Iwasaki K, Arimura S, Sunagawa H, Shiokawa M, Inoue K, Sakono T, Sakono T, Kuwamura R, Yoshida A, Oi J, Kuwayama Y, Kano K, Kido N, Matsuyama A, Ozaki M, Abe H, Inoue C, Nakagawa S, Musashi K, Kanamori A, Lee J, Otani S, Aoki R, Tanabe H, Nakakura S, Suzuki K, Sagara T, Saito Y, Sameshima M, Urahashi M, Watanabe-Kitamura F, Inoue T, Kagaya F, Murai Y, Mori S, Ueda K, Kurimoto T, Yamada-Nakanishi Y, Nakamura M, Yamashita T, Ishiyama S, Manabe S, Takaki K, Hayashi K, Ishida A, Tsutsui A, Manabe K, Tanito M. Inatani M, et al. Adv Ther. 2023 Sep;40(9):4074-4092. doi: 10.1007/s12325-023-02589-9. Epub 2023 Jul 15. Adv Ther. 2023. PMID: 37452961 Free PMC article. Clinical Trial.
INTRODUCTION: This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and tolerability of fixed combinations of 0.1% brimonidine/0.5% timolol (BTFC) versus 1% dorzolamide/0.5% timolol (DTFC) as adjunctive t …
INTRODUCTION: This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and …
Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials.
Ackerman SL, Torkildsen GL, McLaurin E, Vittitow JL. Ackerman SL, et al. Clin Exp Optom. 2019 Mar;102(2):131-139. doi: 10.1111/cxo.12846. Epub 2018 Dec 7. Clin Exp Optom. 2019. PMID: 30525235 Free PMC article. Clinical Trial.
BACKGROUND: The aim of this study was to provide an integrated analysis of safety and efficacy data for brimonidine tartrate ophthalmic solution 0.025 per cent (low-dose; Bausch & Lomb Incorporated), a topical vasoconstrictor for relief of ocular redness. ...RES …
BACKGROUND: The aim of this study was to provide an integrated analysis of safety and efficacy data for brimonidine tartrate o …
Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study.
Tanihara H, Yamamoto T, Aihara M, Koizumi N, Fukushima A, Kawakita K, Kojima S, Nakamura T, Suganami H; K-232 Clinical Study Group. Tanihara H, et al. Graefes Arch Clin Exp Ophthalmol. 2024 Aug;262(8):2579-2591. doi: 10.1007/s00417-024-06388-y. Epub 2024 Mar 2. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 38430227 Free PMC article. Clinical Trial.
PURPOSE: To evaluate the long-term efficacy and safety of ripasudil-brimonidine fixed-dose combination (RBFC), a new intraocular pressure (IOP)-lowering medication for glaucoma and ocular hypertension (OHT). ...
PURPOSE: To evaluate the long-term efficacy and safety of ripasudil-brimonidine fixed-dose combination (RBFC), a new intraocular pres …
Brimonidine displays anti-inflammatory properties in the skin through the modulation of the vascular barrier function.
Bertino B, Blanchet-Réthoré S, Thibaut de Ménonville S, Reynier P, Méhul B, Bogouch A, Gamboa B, Dugaret AS, Zugaj D, Petit L, Roquet M, Piwnica D, Vial E, Bourdès V, Voegel JJ, Nonne C. Bertino B, et al. Exp Dermatol. 2018 Dec;27(12):1378-1387. doi: 10.1111/exd.13793. Exp Dermatol. 2018. PMID: 30290018 Clinical Trial.
Topical pretreatment with brimonidine tartrate 0.33% gel once a day for 4 days significantly prevented neutrophil infiltration by 53.9% in human skin after exposure to UV light. CONCLUSION: Results from in vitro, in vivo and from a clinical study indicate that br …
Topical pretreatment with brimonidine tartrate 0.33% gel once a day for 4 days significantly prevented neutrophil infiltration …
264 results

Searches related to "brimonidine"